New era of personalized medicine:Advanced therapy medicinal products in Europe  

作　　者：Javier García-González Sonia Marhuenda-Castillo Sheila Romero-Carretero Jesús Beltrán-García 

机构地区：[1]Strategy and Market Access,Pharmaceutical Industry,Madrid 28012,Spain [2]Clinical Research,International CRO,Madrid 28003,Spain [3]Department of Physiology,Faculty of Medicine and Dentistry,University of Valencia,Valencia 46010,Spain [4]Center for Biomedical Research in Rare Diseases Network(CIBERER),Carlos III Health Institute,Valencia 46010,Spain [5]INCLIVA Institute of Sanitary Research,Valencia 46010,Spain

出　　处：《World Journal of Immunology》2021年第1期1-10,共10页世界免疫学杂志

摘　　要：Advanced therapy medicinal products are human medical therapies based on genes,cells,or tissues,and due to their characteristics,they offer new innovative opportunities for the treatment of diseases and injuries,especially for diseases beyond the reach of traditional approaches.These therapies are at the forefront of innovation and have historically been very controversial,although in the last decade they have gained prominence while the number of new advanced therapies has increased every year.In this regard,despite the controversy they may generate,they are expected to dominate the market in the coming decades.Technologies based on advanced therapies are the present and future of medicine and bring us closer to the long-awaited precision medicine.Here we review the field as it stands today,with a focus on the molecular mechanisms that guided the different advanced therapies approved by the European Medicines Agency,their current status,and their legal approval.

关 键 词：Advanced therapy Advanced therapy medicinal products Cell therapy Gene therapy Tissue therapy Chimeric antigen receptor T cell 

分 类 号：R73[医药卫生—肿瘤]